Compare Main Street Capital Corporation (MAIN) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Zimmer Biomet Holdings Inc — how do they compare? Main Street Capital Corporation trades at $54.14 (market cap $5.09B), while Zimmer Biomet Holdings Inc trades at $89.08 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 3.3× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays the higher dividend (5.84%). Which is the better fit depends on your goals — on Pluang, investors hold Main Street Capital Corporation for 88 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| MAIN | ZBH | |
|---|---|---|
Market Cap | $5.09B | $16.95B |
Volume | 524,060 | 2,505,240 |
Sector | Financials | Health |
52-Week High | $64.60 | $103.98 |
52-Week Low | $49.63 | $79.58 |
Typical Hold Time | 88 Days | 89 Days |
Enterprise Value | $7.54B | $24.02B |
Dividend Yield | 5.84% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $54.305, up 0.23% on the day, with a bearish technical outlook as moving averages and oscillators signal selling pressure. Fundamentally, the company maintains strong profitability with an 80.77% net income margin and a P/E of 10.94, though revenue declined to $592 million in 2025 from $601 million in 2024. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026. The stock pays consistent monthly dividends, with the latest being $0.27 per share.
The investment outlook is cautious; analyst consensus is a 'Hold' with a $58.33 price target, indicating modest upside. Risks include softening earnings, a premium valuation at 1.62x NAV, and sensitivity to interest rates. The bearish technicals and high hold ratings suggest limited near-term catalysts, but the dividend yield near 8% and robust ROE of 14.92% provide income support.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
